60 Degrees Pharmaceuticals regains Nasdaq compliance on minimum bid price; delisting hearing cancelled

60 DEGREES PHARMACEUTICALS, INC.

Received Nasdaq notice on Feb 11 confirming compliance with minimum bid price rule 5550(a)(2).
Prior delisting notice from Jan 20, 2026 was appealed and stayed pending hearing.
Hearing scheduled for Feb 19, 2026 has been cancelled; matter closed.
Company's common stock and warrants continue trading on Nasdaq Capital Market.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.